Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

AIM: To investigate the effects of semaglutide versus comparators on major adverse cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] and nonfatal stroke) and hospitalization for heart failure (HF) in the SUSTAIN (subcutaneous semaglutide) and PIONEER (oral s...

Descripción completa

Detalles Bibliográficos
Autores principales: Husain, Mansoor, Bain, Stephen C., Jeppesen, Ole K., Lingvay, Ildiko, Sørrig, Rasmus, Treppendahl, Marianne B., Vilsbøll, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064975/
https://www.ncbi.nlm.nih.gov/pubmed/31903692
http://dx.doi.org/10.1111/dom.13955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064975/
https://www.ncbi.nlm.nih.gov/pubmed/31903692
http://dx.doi.org/10.1111/dom.13955

Ejemplares similares